Seroprevalence of Infection-induced SARS-CoV-2 Antibodies (COVID-19) in Children
1 other identifier
observational
4,032
1 country
1
Brief Summary
It is unknown what proportion of children have been exposed to SARS-CoV-2 and how many have antibodies among children seeking medical care for non-Covid-19 related conditions. The aim of this study is to identify children with IgG antibodies to SARS-CoV-2 who have not been previously diagnosed and are presumed/confirmed Covid-19 negative, then determine the level of immunity in this population which could inform further decisions about covid-19 vaccine strategies for children
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 13, 2022
CompletedFirst Submitted
Initial submission to the registry
April 30, 2022
CompletedFirst Posted
Study publicly available on registry
May 3, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 5, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
November 13, 2022
CompletedMarch 9, 2023
March 1, 2023
3 months
April 30, 2022
March 8, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
The percentage of children with IgG SARS-CoV-2 antibodies in Plasma
The percentage of children with IgG SARS-CoV-2 antibodies to the total number of children enrolled in the study
6 month
Immunoglobulins (G) to SARS-CoV-2 in plasma
Mean antibody titres (IgG) to SARS-CoV-2 in plasma using SIEMENS assays
6 month
Secondary Outcomes (1)
Measure of association between SARS-CoV-2 IgG seropositivity and characteristics
6 month
Interventions
IgG Antibody testing for previous exposure to SARS-CoV-2
Eligibility Criteria
In-patient or out-patient children aged from 0 to 18 years old, who have not have not been previously diagnosed and are presumed/confirmed COVID-19 negative, have blood specimens collected for routine biochemistry tests.
You may qualify if:
- Age ≤ 18 years old.
- Seeking medical care at Vietnam National Children's Hospital for any condition not related to acute Covid-19
- Have not been previously diagnosed and are presumed/confirmed COVID-19 negative
- Have blood specimens collected for any routine biochemistry test on the date enrollment
You may not qualify if:
- Refusal to participate in this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Vietnam National Children's Hospital
Hanoi, Vietnam
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Phuc H Phan, MD
Vietnam National Children's Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Physician
Study Record Dates
First Submitted
April 30, 2022
First Posted
May 3, 2022
Study Start
March 13, 2022
Primary Completion
June 5, 2022
Study Completion
November 13, 2022
Last Updated
March 9, 2023
Record last verified: 2023-03